Form 4: NeuroOne Medical Technologies CEO Disposes of Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


NeuroOne Medical Technologies CEO David A. Rosa disposed of 2,239 shares of common stock on March 31, 2024, to satisfy tax withholding obligations.

Summary

  • On March 31, 2024, David A. Rosa, CEO and President of NeuroOne Medical Technologies Corp, disposed of 2,239 shares of common stock.
  • The transaction was executed at a price of $1.2 per share.
  • This disposal was related to the satisfaction of tax withholding obligations.
  • Following the transaction, Rosa directly owns 1,184,509 shares of NeuroOne Medical Technologies Corp.

Sentiment

Score: 5

Explanation: The document simply reports a transaction related to tax obligations, which is neutral in sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

  • The disposal of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the transaction.

Key Dates

DateDescription
03/31/2024Date of transaction: Disposal of shares.
04/02/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.